[ad_1] Vlado Perkovic, PhD Janssen Pharmaceutical Johnson & Johnson companies announced the early end of a phase 3 of canagliflozin (Invokana) for the treatment of patients with chronic renal failure and type …
Read More »Janssen terminates Canagliflozin's CREDENCE test soon after reaching T2D, CKD Endpoints
